Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Cancer Immunology, Immunotherapy
Erschienen in: Cancer Immunology, Immunotherapy 4/2006

01.04.2006 | Original Article

Interferon-α/β upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-α/β treatment

verfasst von: Kouzaburo Yamaji, Shigeki Nabeshima, Masayuki Murata, Yong Chong, Norihiro Furusyo, Hideyuki Ikematsu, Jun Hayashi

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Type I interferon (IFN) possesses antiviral and antitumor activities and also having an immune regulatory effect, activating cellular immune response and upregulating several cytokines. Recent study has shown that type I IFN upregurates the dendritic cell production of IL-15 capable of activating natural killer cells and CD8+ memory T lymphocytes. However, it is still unknown if type I IFN induces IL-15 production in non-immune cells and if type I IFN affects IL-15 production in vivo. The present study investigated the effect of type I IFNs on IL-15 expression in hepatocellular carcinoma (HCC) cell lines in vitro and in patients with chronic hepatitis C in vivo. When three HCC cell lines, Huh7, HepG2, and JHH4 were cultured in vitro, IFN upregulation of IL-15 expression was observed at both the mRNA and protein levels. In experiments using Huh7 cells, upregulation of IL-15 expression occurred within 24 h of the start of IFN stimulation, and both IFN-α and -β dose-dependently increased IL-15 production in the range from 100 U/ml to 10,000 U/ml of concentration. IFN-β showed stronger activity in IL-15 production induction in vitro than IFN-α. For in vivo examination, sera were obtained from 21 chronic hepatitis C patients treated with IFN and 29 healthy individuals, and the serum IL-15 level was quantified by ELISA. The serum IL-15 level of chronic hepatitis C patients before IFN treatment was similar to that of the healthy controls and significantly increased only during the IFN administration period. These results confirm that IFN-α/β induce IL-15 production and also suggest that IL-15 may be associated with type I IFN-induced immune response.
Literatur
1.
Alter HJ (1995) To C or not to C: these are the questions. Blood 85:1681–1695PubMed
2.
Tong MJ, el-Farra NS, Reikes AR et al (1995) Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332:1463–1466CrossRefPubMed
3.
Tanaka K, Ikematsu H, Hirohata T et al (1996) Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. J Natl Cancer Inst 88:742–746PubMedCrossRef
4.
Tagger A, Donato F, Ribero ML et al (1999) Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 81:695–699CrossRefPubMed
5.
Hayashi J, Furusyo N, Ariyama I et al (2000) A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 181:1523–1527CrossRefPubMed
6.
Davis GL, Balart LA, Schiff ER et al (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 321:1501–1506PubMedCrossRef
7.
Di Bisceglie AM, Martin P, Kassianides C et al (1989) Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506–1510PubMedCrossRef
8.
Kakumu S, Arao M, Yoshioka K et al (1990) Recombinant human alpha-interferon therapy for chronic non-A, non-B hepatitis: second report. Am J Gastroenterol 85:655–659PubMed
9.
Hayashi J, Ohmiya M, Kishihara Y et al (1994) A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 89:2151–2156PubMed
10.
Hayashi J, Kishihara Y, Ueno K et al (1998) Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 158:177–181CrossRefPubMed
11.
Furusyo N, Hayashi J, Ohmiya M et al (1999) Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci 44:608–617CrossRefPubMed
12.
Nishiguchi S, Kuroki T, Nakatani S et al (1995) Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051–1055CrossRefPubMed
13.
Yoshida H, Shiratori Y, Moriyama M et al (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 131:174–181PubMed
14.
Kashiwagi K, Furusyo N, Kubo N et al (2003) A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother 9:333–340CrossRefPubMed
15.
Stark GR, Kerr IM, Williams BR et al (1998) How cells respond to interferons. Annu Rev Biochem 67:227–264CrossRefPubMed
16.
Meurs EF, Galabru J, Barber GN et al (1993) Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 90:232–236PubMedCrossRef
17.
Yano H, Iemura A, Haramaki M et al (1999) Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 29:1708–1717CrossRefPubMed
18.
Murphy D, Detjen KM, Welzel M et al (2001) Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 33:346–356CrossRefPubMed
19.
Takaoka A, Hayakawa S, Yanai H et al (2003) Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424:516–523CrossRefPubMed
20.
von Hoegen P (1995) Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes. Immunol Lett 47:157–162CrossRefPubMed
21.
Hiroishi K, Tuting T, Lotze MT (2000) IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol 164:567–572PubMed
22.
Biron CA, Nguyen KB, Pien GC et al (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17:189–220CrossRefPubMed
23.
Ohzato H, Monden M, Yoshizaki K et al (1993) Systemic production of interleukin-6 following acute inflammation. Biochem Biophys Res Commun 197:1556–1562CrossRefPubMed
24.
Kawakami Y, Hayashi J, Ueno K et al (1997) Elevation of serum soluble interleukin-2 receptor levels in patients with hepatitis C virus infection. Fukuoka Igaku Zasshi 88:274–282PubMed
25.
Mattei F, Schiavoni G, Belardelli F et al (2001) IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol 167:1179–1187PubMed
26.
Grabstein KH, Eisenman J, Shanebeck K et al (1994) Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264:965–968PubMedCrossRef
27.
Carson WE, Giri JG, Lindemann MJ et al (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180:1395–1403CrossRefPubMed
28.
Kennedy MK, Glaccum M, Brown SN et al (2000) Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191:771–780CrossRefPubMed
29.
Sharif-Askari E, Fawaz LM, Tran P et al (2001) Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture. J Natl Cancer Inst 93:1724–1732CrossRefPubMed
30.
Lodolce JP, Boone DL, Chai S et al (1998) IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9:669–676CrossRefPubMed
31.
Zhang X, Sun S, Hwang I et al (1998) Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8:591–599CrossRefPubMed
32.
Liu K, Catalfamo M, Li Y et al (2002) IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells. Proc Natl Acad Sci USA 99:6192–6197CrossRefPubMed
33.
Hayashi J, Yoshimura E, Kishihara Y et al (1996) Hepatitis C virus RNA levels determined by branched DNA probe assay correlated with levels assessed using competitive PCR. Am J Gastroenterol 91:314–318PubMed
34.
Strehlau J, Pavlakis M, Lipman M et al (1997) Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 94:695–700CrossRefPubMed
35.
Smith XG, Bolton EM, Ruchatz H et al (2000) Selective blockade of IL-15 by soluble IL-15 receptor alpha-chain enhances cardiac allograft survival. J Immunol 165:3444–3450PubMed
36.
Conti F, Frappier J, Dharancy S et al (2003) Interleukin-15 production during liver allograft rejection in humans. Transplantation 76:210–216CrossRefPubMed
37.
McInnes IB, al-Mughales J, Field M et al (1996) The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 2:175–182CrossRefPubMed
38.
McInnes IB, Leung BP, Sturrock RD et al (1997) Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 3:189–195CrossRefPubMed
39.
Lu J, Giuntoli RL, 2nd, Omiya R et al (2002) Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res 8:3877–3884PubMed
40.
Lewko WM, Smith TL, Bowman DJ et al (1995) Interleukin-15 and the growth of tumor derived activated T-cells. Cancer Biother 10:13–20PubMed
41.
Yajima T, Nishimura H, Ishimitsu R et al (2002) Overexpression of IL-15 in vivo increases antigen-driven memory CD8+ T cells following a microbe exposure. J Immunol 168:1198–1203PubMed
42.
Klebanoff CA, Finkelstein SE, Surman DR et al (2004) IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 101:1969–1974CrossRefPubMed
43.
Fehniger TA, Cooper MA, Caligiuri MA (2002) Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 13:169–183CrossRefPubMed
44.
Brentjens RJ, Latouche JB, Santos E et al (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9:279–286PubMedCrossRef
45.
Wang T, Niu G, Kortylewski M et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48–54CrossRefPubMed
46.
Radaeva S, Jaruga B, Hong F et al (2002) Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 122:1020–1034CrossRefPubMed
47.
Azimi N, Shiramizu KM, Tagaya Y et al (2000) Viral activation of interleukin-15 (IL-15): characterization of a virus-inducible element in the IL-15 promoter region. J Virol 74:7338–7348CrossRefPubMed
48.
Jinushi M, Takehara T, Tatsumi T et al (2003) Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J Immunol 171:5423–5429PubMed
49.
Damdinsuren B, Nagano H, Sakon M et al (2003) Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol 10:1184–1190CrossRefPubMed
50.
Domanski P, Nadeau OW, Platanias LC et al (1998) Differential use of the betaL subunit of the type I interferon (IFN) receptor determines signaling specificity for IFNalpha2 and IFNbeta. J Biol Chem 273:3144–3147CrossRefPubMed
51.
Rani MR, Foster GR, Leung S et al (1996) Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem 271:22878–22884CrossRefPubMed
52.
Rani MR, Gauzzi C, Pellegrini S et al (1999) Induction of beta-R1/I-TAC by interferon-beta requires catalytically active TYK2. J Biol Chem 274:1891–1897CrossRefPubMed
53.
Yamaji K, Hayashi J, Kawakami Y et al (1998) Hepatitis C viral RNA status at two weeks of therapy predicts the eventual response. J Clin Gastroenterol 26:193–199CrossRefPubMed
Metadaten
Titel
Interferon-α/β upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-α/β treatment
verfasst von
Kouzaburo Yamaji
Shigeki Nabeshima
Masayuki Murata
Yong Chong
Norihiro Furusyo
Hideyuki Ikematsu
Jun Hayashi
Publikationsdatum
01.04.2006
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 4/2006
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-005-0005-x

Weitere Artikel der Ausgabe 4/2006

Cancer Immunology, Immunotherapy 4/2006 Zur Ausgabe

Original Article

Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro

Original Article

Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice

Meeting Report

Cancer Immunotherapy 2005: Mainz, Germany, 12–13 May 2005

Original Article

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients

Original Article

Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells

Original Article

Importance of signaling via the IFN-α/β receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise